SI
SI
discoversearch

Biotech / Medical : Biotech Valuation

 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  
To: Jon Khymn who wrote (31358)5/30/2009 5:24:14 PM
From: Biomaven1 Recommendation  Read Replies (2) of 42601
 
Unfortunately there is a third possibility that is not at all unlikely here - the panel votes narrowly in favor of the drug. In that case the FDA could ultimately decide to require more data - Provenge is a good example of that happening.

The stock probably goes down on that narrowly-in-favor vote, but certainly nowhere near enough to avoid you getting killed on the straddle.

Peter
Report TOU ViolationShare This Post
 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  

Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.